Mesoblast's Ryoncil Q1 Sales Hit $30 Mln
Mesoblast Limited (MESO), an allogenic cellular medicines company, released on Friday the first quarter financial reports, provided updates on the company's lead product, Ryoncil, and other operational highlights. Mesoblast's flagship product, …